logo dark logo light logo
  • 首页
  • 关于我们
    • 背景
    • 投资战略
    • 团队
  • 投资组合
  • 新闻中心
  • 联系我们
  • English
  • 投资者登录
mobile-logo
  • 首页
  • 关于我们
    • 背景
    • 投资战略
    • 团队
  • 投资组合
  • 新闻中心
  • 联系我们
  • English
  • 投资者登录
 

新闻中心

30 1月 2020
by admin
in Uncategorized
Comments
TEMPEST THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR TPST-1495 AND WELCOMES NEW INVESTORS
20 12月 2019
by admin
in Uncategorized
Comments
Syros Announces Appointment of Mark Alles to Its Board of Directors
18 12月 2019
by admin
in Uncategorized
Comments
GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia
03 12月 2019
by admin
in Uncategorized
Comments
Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975
19 11月 2019
by admin
in Uncategorized
Comments
NextCure Announces Closing of Public Offering
15 11月 2019
by admin
in Uncategorized
Comments
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24

中国上海市浦东新区张江高科技园区金科路4560号金创大厦3号楼8楼,201210
电话: +86 21 6163 2598  |  传真: +86 21 6163 2570  |  邮件: info@quancapital.com

© Quan Capital. All rights reserved. Credit: Website Design